



# SEQUENCE LISTING

<110> Ball, Kathryn L  
Lane, David P

<120> Methods and Means for Inhibition of CDK4 Activity

<130> CCI-007USDV

<140> US 10/646,267

<141> 2003-08-22

<150> US 09/180,269

<151> 1999-07-08

<150> PCT/GB97/01250

<151> 1997-05-08

<150> GB 9609521.1

<151> 1996-05-08

<150> GB 9621314.5

<151> 1996-10-09

<160> 28

<170> PatentIn Ver. 2.1

<210> 1

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 1

Met	Ser	Glu	Pro	Ala	Gly	Asp	Val	Arg	Gln	Asn	Pro	Cys	Gly	Ser	Lys
1				5				10					15		

Ala	Cys	Arg	Arg
			20

<210> 2

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 2

Lys	Ala	Cys	Arg	Arg	Leu	Phe	Gly	Pro	Val	Asp	Ser	Glu	Gln	Leu	Ser
1				5				10					15		

Arg Asp Cys Asp  
20

<210> 3  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 3  
Ser Arg Asp Cys Asp Ala Leu Met Ala Gly Cys Ile Gln Glu Ala Arg  
1 5 10 15

Glu Arg Trp Asn  
20

<210> 4  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 4  
Arg Glu Arg Trp Asn Phe Asp Phe Val Thr Glu Thr Pro Leu Glu Gly  
1 5 10 15

Asp Phe Ala Trp  
20

<210> 5  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 5  
Gly Asp Phe Ala Trp Glu Arg Val Arg Gly Leu Gly Leu Pro Lys Leu  
1 5 10 15

Tyr Leu Pro Thr  
20

<210> 6

<211> 20  
<212> .PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthesised

<400> 6  
Leu Tyr Leu Pro Thr Gly Pro Arg Arg Gly Arg Asp Glu Leu Gly Gly  
1 5 10 15  
Gly Arg Arg Pro  
20

<210> 7  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthesised

<400> 7  
Gly Gly Arg Arg Pro Gly Thr Ser Pro Ala Leu Leu Gln Gly Thr Ala  
1 5 10 15  
Glu Glu Asp His  
20

<210> 8  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthesised

<400> 8  
Ala Glu Glu Asp His Val Asp Leu Ser Leu Ser Cys Thr Leu Val Pro  
1 5 10 15  
Arg Ser Gly Glu  
20

<210> 9  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthesised

<400> .9

Pro Arg Ser Gly Glu Gln Ala Glu Gly Ser Pro Gly Gly Pro Gly Asp  
1 5 10 15

Ser Gln Gly Arg  
20

<210> 10

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 10

Lys Arg Arg Gln Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg  
1 5 10 15

Leu Ile Phe Ser  
20

<210> 11

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 11

Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser  
1 5 10 15

Lys Arg Lys Pro  
20

<210> 12

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Motif

<400> 12

Arg Arg Leu Ile Phe  
1 5

<210> .13  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Motif

<400> 13  
Lys Arg Arg Leu Ile Phe Ser Lys  
1 5

<210> 14  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<221> SITE  
<222> (2)..(3)  
<223> Xaa may be any amino acid

<220>  
<221> SITE  
<222> 6, 8  
<223> Xaa may be hydrophobic

<220>  
<221> SITE  
<222> 1, 9  
<223> Xaa may be absent or may be any amino acid

<220>  
<223> Description of Artificial Sequence: General  
formula

<400> 14  
Xaa Xaa Xaa Arg Arg Xaa Phe Xaa Xaa  
1 5

<210> 15  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Carrier  
peptide

<400> 15  
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys

1 5 10 15

<210> 16  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthesised

<400> 16  
Pro Arg Ser Gly Glu Gln Ala Glu Gly Ser Pro Gly Gly Pro Gly Asp  
1 5 10 15

Ser Gln Gly Arg  
20

<210> 17  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthesised

<400> 17  
Glu Gln Ala Glu Gly Ser Pro Gly Gly Pro Gly Asp Ser Gln Gly Arg  
1 5 10 15

Lys Arg Arg Gln  
20

<210> 18  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthesised

<400> 18  
Gly Ser Pro Gly Gly Pro Gly Asp Ser Gln Gly Arg Lys Arg Arg Gln  
1 5 10 15

Thr Ser Met Thr  
20

<210> 19  
<211> 20

<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 19

Gly Pro Gly Asp Ser Gln Gly Arg Lys Arg Arg Gln Thr Ser Met Thr  
1 5 10 15

Asp Phe Tyr His  
20

<210> 20

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 20

Ser Gln Gly Arg Lys Arg Arg Gln Thr Ser Met Thr Asp Phe Tyr His  
1 5 10 15

Ser Lys Arg Arg  
20

<210> 21

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 21

Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser  
1 5 10 15

Lys Arg Lys Pro  
20

<210> 22

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 22

Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser Lys Arg Lys Pro  
1 5 10 15

<210> 23

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Truncated  
peptide

<400> 23

Lys Arg Arg Leu Ile Phe Ser Lys  
1 5

<210> 24

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 24

Lys Arg Arg Gln Thr Ser Ala Thr Asp Phe Tyr His Ser Lys Arg Arg  
1 5 10 15

Leu Ile Phe Ser Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met  
20 25 30

Lys Trp Lys Lys  
35

<210> 25

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 25

Lys Arg Arg Leu Ile Phe Ser Lys Arg Gln Ile Lys Ile Trp Phe Gln  
1 5 10 15

Asn Arg Arg Met Lys Trp Lys Lys  
20



<210> 26  
<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthesised

<400> 26  
Arg Gln Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Arg Gln  
1 5 10 15  
Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys  
20 25 30

<210> 27  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthesised

<400> 27  
Gln Thr Ser Met Thr Asp Phe Tyr  
1 5

<210> 28  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthesised

<400> 28  
Lys Arg Arg Gln Thr Ser Ala Thr Asp Phe Tyr His Ser Lys Arg Arg  
1 5 10 15  
Leu Ile Phe Ser  
20